Costs of atrial fibrillation in five European countries: Results from the Euro Heart Survey on atrial fibrillation

Europace

Volumn 10, Issue 4, 2008, Pages 403-411

  Ringborg, Anna ^a,b   Nieuwlaat, Robby ^c   Lindgren, Peter ^a,b   Jönsson, Bengt ^d   Fidan, Dogan ^e   Maggioni, Aldo P ^f   Lopez Sendon, Jose ^g   Stepinska, Janina ^h   Cokkinos, Dennis V ⁱ   Crijns, Harry J G M ^c  

^a i3 Innovus ^*  (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^e SANOFI   (France)

^f ANMCO RESEARCH CENTER   (Italy)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h INSTITUTE OF CARDIOLOGY   (Poland)

ⁱ ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

Atrial fibrillation; Burden; Cost; Economic; Resource use

Indexed keywords

ACENOCOUMAROL; CLOPIDOGREL; DIGOXIN; LOW MOLECULAR WEIGHT HEPARIN; SOTALOL;

ADULT; AGED; ARTICLE; CARDIOVERSION; CATHETERIZATION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; COST BENEFIT ANALYSIS; DEFIBRILLATOR; ELECTROCARDIOGRAM; ELECTROPHYSIOLOGY; EUROPE; HEALTH CARE COST; HEALTH SURVEY; HEART ATRIUM FIBRILLATION; HEART VALVE REPLACEMENT; HUMAN; MAJOR CLINICAL STUDY; PACEMAKER; PATIENT CARE; PRIORITY JOURNAL;

AGED; ATRIAL FIBRILLATION; FEMALE; FOLLOW-UP STUDIES; GREECE; HEALTH CARE SURVEYS; HEALTH RESOURCES; HOSPITAL COSTS; HUMANS; INPATIENTS; ITALY; MALE; NETHERLANDS; PATIENT ADMISSION; POLAND; SPAIN;

EID: 44449119900     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eun048     Document Type: Article

References (24)

1. Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database. Heart 2001;86:284-8.
2. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-53.
3. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370- 5.
4. Rosamond WD, Chambless LE, Folsom AR, Cooper LS, Conwill DE, Clegg L et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 1998;339:861-7.
5. Ekman M. Economic evidence in stroke: a review. Eur J Health Econ 2004;5:S74-S83.
6. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978;28:973-7.
7. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005;26:2422-34.
8. WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index 2005 (1 December 2005 date last accessed). http://www.whocc.no/atcddd.
9. van Hout BA, Serruys PW, Lemos PA, van den Brand MJ, van Es GA, Lindeboom WK et al. One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial. Heart 2005;91:507-12.
10. van Alem AP, Dijkgraaf MG, Tijssen JG, Koster RW. Health system costs of out-of-hospital cardiac arrest in relation to time to shock. Circulation 2004;110:1967-73.
11. Kobelt G, Berg J, Lindgren P, Fredrikson S, Jonsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006;77:918-26.
12. Eurostat, Long-term indicators - Economy and finance (16 November 2007, date last accessed). http://epp.eurostat.ec.europa.eu.
13. Eurostat, Long-term indicators - Population and social conditions (10 May 2007, date last accessed). http://epp.eurostat.ec.europa.eu.
14. Dell'Orfano JT, Patel H, Wolbrette DL, Luck JC, Naccarelli GV. Acute treatment of atrial fibrillation: spontaneous conversion rates and cost of care. Am J Cardiol 1999;83:788-90, A10.
15. Wu EQ, Birnbaum HG, Mareva M, Tuttle E, Castor AR, Jackman W et al. Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin 2005;21:1693-9.
16. Reynolds MR, Essebag V, Zimetbaum P, Cohen DJ. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol 2007;18:628-33.
17. Le Heuzey JY, Paziaud O, Piot O, Said MA, Copie X, Lavergne T et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J 2004;147:121-6.
18. Stewart S, Murphy N, Walker A, McGuire A, McMurray JJ. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004;90:286-92.
19. Hagens VE, Vermeulen KM, TenVergert EM, Van Veldhuisen DJ, Bosker HA, Kamp O et al. Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation-results from the RAte Control versus Electrical cardioversion (RACE) study. Eur Heart J 2004;25:1542-9.
20. Pietrasik A, Kosior DA, Niewada M, Opolski G, Latek M, Kaminski B. The cost comparison of rhythm and rate control strategies in persistent atrial fibrillation. Int J Cardiol 2007;118:21-7.
21. Briggs A, Clark T, Wolstenholme J, Clarke P. Missing. . . presumed at random: cost-analysis of incomplete data. Health Econ 2003;12:377-92.
22. Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003;14:666-72.
23. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003;108:711-6.
24. Heeg BM, Peters RJ, Botteman M, van Hout BA. Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention. Pharmacoeconomics 2007;25:769-82.